

PV Reporter Publishes Molecular Remission Roadmap

Charlotte blood cancer advocate David Wallace shares lessons from six years with undetectable disease ahead of Blood Cancer Awareness Month.

CHARLOTTE, NC, UNITED STATES, August 11, 2026 /EINPresswire.com/ -- [PV Reporter](#) today announced the publication of a patient education resource detailing founder David Wallace's path to complete molecular remission from polycythemia vera (PV), a rare blood cancer. Released ahead of Blood Cancer Awareness Month in September, the resource gives patients information they can use to discuss driver mutations, treatment goals and MPN specialist care with their physicians.

The resource is available at <https://pvreporter.com/polycythemia-vera-molecular-remission/>.

Wallace was diagnosed with PV in 2009. His blood counts are normal, and the JAK2 mutation that caused his disease has remained undetectable for more than six years. His JAK2 V617F allele burden fell from roughly 28 percent to undetectable, an outcome described as complete molecular remission. Remission is not a cure, and treatment outcomes vary widely among patients.

The new resource describes Wallace's progression from phlebotomy to pegylated interferon and then combination therapy with ruxolitinib. It also explains how research he found while attending the 2015 American Society of Hematology annual meeting led him to discuss the combination with his physician. During treatment, Wallace developed skin cancer requiring continued monitoring, experienced infections and went through repeated dose changes. He remains on low-dose maintenance therapy.

Wallace went through five hematologists during the early years of his PV journey while searching broadly for a physician with strong MPN expertise and a willingness to discuss current research. His changes in physicians reflected a broader search for informed care and were not specifically related to combination therapy. After asking the chief of hematology at his cancer center for "a doctor who knows more about PV than I do," he was referred to the specialist who still treats him.

"Most PV patients are never told that deep remission is even on the table," Wallace said. "Newly diagnosed patients must learn about their illness, understand what each treatment is intended

to accomplish and make sure they are seeing a true MPN specialist."

Published research shows that deep molecular responses are possible with pegylated interferon alone and in combination with ruxolitinib, although outcomes vary and complete molecular remission remains uncommon. The resource also directs patients to PV Reporter's free, doctor-vetted MPN Specialist Locator at <https://pvreporter.com/mpn-specialists-cancer-treatment-centers/>.

About PV Reporter

PV Reporter was founded by David Wallace in 2013 to provide patient-friendly information about myeloproliferative neoplasms. The site publishes emerging MPN research and maintains a doctor-vetted specialist locator and a free clinical trial finder. Through PV Reporter and the nonprofit MPN Cancer Connection, Wallace has supported thousands of patients and caregivers worldwide.

David Wallace
PV Reporter
+1 704-323-6771
david@pvreporter.com

This press release can be viewed online at: <https://www.einpresswire.com/article/933411771>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.